Researchers from the Nutrition Research Center of the University of Navarra seek volunteers with type 2 diabetesbetween 18 and 70 years old, to participate in the DiabeT2Predict projectan innovative initiative aimed at improving the control of this disease.
The combination of advances in the analysis of the intestinal microbiota and genetic tools will allow the application of a precision nutrition approach for greater control of type 2 diabetes based on the genetic profile and the modulation of the microbiota of the participants. Volunteers will receive a specialized care and exhaustive clinical follow-upin order to personalize interventions and improve blood glucose control according to the individual characteristics of each patient. To participate in the study you must write an email to [email protected] or call 948 425 744.
“Our goal is to apply personalized nutrition through supplementation with probiotics and postbiotics to address glycemic control, better understanding the particularities of each patient and adapting the treatment according to their genetics and intestinal microbiota,” he points out. Pedro González Muniesaprincipal investigator of the study at the University of Navarra. “This approach will allow offer nutritional solutions based on supplementation with microbiota modulators as a novel strategy that is more effective and compatible with medication and contributes to reducing the health impact of type 2 diabetes in Spain, which currently represents 9% of total health spending.”
The project is promoted by a consortium of research entities and biotechnology companies. Led by Genbioma in collaboration with Patia, the Biobizkaia Health Research Institute and several teams from the University of Navarra (the University of Navarra Clinic, CRO, CIMA LAB Diagnostics and the Nutrition Research Center), the study has a financing of 1.7 million euros by the Ministry of Science and Innovation and is also financed by the European Union.
As part of the study, the effectiveness of a probiotic/postbiotic formula developed by Genbiomawith which it is intended regulate blood glucose by modulating the intestinal microbiota. Furthermore, thanks to an advanced genetic prediction tool, developed by Patia, researchers will be able to adapt the recommendations to the physiology of each patient, allowing more conscious and personalized decision-making in the management of their health.
Type 2 diabetes constitutes a global pandemic, and Spain is currently the second European country with the highest incidence rate of this disease, with about 400,000 new diagnoses annually in adults. “The novelty of this study is that we do not intend to replace pharmacological treatment, but rather to provide each patient with all the information they need to change their lifestyle and eating habits, so that supplementation with postbiotics is as effective as possible,” he explains. González Muniesa.
Furthermore, since it is a nutritional intervention with postbiotics as safe nutritional supplements that have been previously tested together with diabetes medication, transfer of laboratory research to patients It is much more direct and no side effects or interactions with drugs are expected, making it safer.
